Alan Akira, MD
Psychiatry · Chicago, ILNPI 1710470257
Payments from drug & device makers
Across 27 payments — averaging $172.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$559
- Alkermes, Inc.$285
- Johnson & Johnson$272
- E.r. Squibb & Sons, L.L.C.$144
- Neurocrine Biosciences, Inc.$124
- plus $324 from 3 others
What the payments were for
- Consulting fees$1,23026%
- Speaking & faculty fees$1,23026%
- Food & beverage$2,18447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $2,936 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $559 |
| Alkermes, Inc. | 4 | $285 |
| Johnson & Johnson | 3 | $272 |
| E.r. Squibb & Sons, L.L.C. | 1 | $144 |
| Neurocrine Biosciences, Inc. | 1 | $124 |
| Indivior Inc. | 1 | $119 |
| AbbVie | 1 | $111 |
| Tris Pharma Inc | 2 | $94 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,644 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $11,905 |
| Clozapine | 186 | $10,833 |
| Clozapine OdtClozapine | 45 | $6,593 |
| Risperidone OdtRisperidone | 26 | $3,902 |
| Paliperidone ErPaliperidone | 22 | $1,626 |
| Haloperidol | 41 | $961 |
| Lithium Carbonate ErLithium Carbonate | 34 | $680 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 56 | $608 |
| Haloperidol Decanoate | 11 | $538 |
| Valproic AcidValproic Acid (As Sodium Salt) | 16 | $430 |
| Perphenazine | 30 | $400 |
| Lurasidone Hcl | 14 | $388 |
| Trazodone Hcl | 60 | $324 |
| Quetiapine Fumarate | 49 | $313 |
| Benztropine Mesylate | 37 | $309 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Chicago
- Yuhwen ChowChicago$8.5M
- Jon GrantChicago$1.4M
- Jeffrey RadoChicago$1.2M
- Mitchell GlaserChicago$1.1M
- Peter WeidenChicago$941K
- Brett PlylerChicago$293K
- Michelle DeesChicago$289K
- Jennifer SpragueChicago$288K
- K Ranga KrishnanChicago$92K
- Pawel DudekChicago$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.